JOURNAL ARTICLE

FDA advisory committee rejects MDMA application for PTSD, but...

  • Published In: Alcoholism & Drug Abuse Weekly, 2024, v. 36, n. 23. P. 5 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Knopf, Alison 3 of 3

Abstract

Last week, the Food and Drug Administration (FDA) voted 9‐2 to reject the application of Lykos Therapeutics, the newly formed commercial arm of MAPS, for "midomafetamine" (actually MDMA, or methylenedioxymethamphetamine) to treat post‐traumatic stress disorder (PTSD). [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Alcoholism & Drug Abuse Weekly. 2024/06, Vol. 36, Issue 23, p5
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2024
  • ISSN:1042-1394
  • DOI:10.1002/adaw.34151
  • Accession Number:177740833
  • Copyright Statement:Copyright of Alcoholism & Drug Abuse Weekly is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.